SenoRx Sets IPO Terms

SenoRx Inc., an Aliso Viejo, Calif.-based provider of minimally-invasive medical devices for the diagnosis and treatment of breast cancer, has set its proposed IPO terms to 5.5 million common shares being offered at between $11 and $13 per share. It plans to trade on the Nasdaq under ticker symbol SENO, with Banc of America Securities and Citigroup serving as co-lead underwriters. The company has raised $54.57 million in total VC funding since its 1998 inception, from firms like MPM Capital, Domain Associates, Mayfield, Medicus Venture Partners, De Novo Ventures, Entrepreneurs' Fund and Tyco Capital (shares now held by Protostar Equity Partners). www.senorx.com